Jan Wyrwiński

Recruitment Smart is a Generative AI tech startup on a global mission of bringing the AI revolution in improving Talent Acquisition, with operations in 70+ countries. Fusing the expertise of industry veterans from recruitment and tech, our solutions are powered by the cutting-edge Generative AI technology. We are committed to addressing diverse customer needs, and craft products finely attuned to the demands of enterprise, mid-size, and startup businesses. Our talent intelligence solutions seamlessly integrates across platforms at organisational scales. At Recruitment Smart, we redefine the future of recruitment by marrying AI innovation with expertise. Join us on our mission to reshape the global recruitment landscape, where technology meets talent seamlessly for unparalleled insights and success.

DEBN (Drug-Eluting Biopsy Needle) is a medical company developing a novel prostate biopsy needle for urologists which will reduce infectious complication rate. -- Overview -- Prostate cancer is the most common malignancy diagnosed among men in developed countries. The prostate biopsy is a gold standard for detecting this cancer. During this procedure, urologists use a disposable biopsy needle to collect samples of tissue for further analysis. Due to the invasive method of diagnosis patients are advised for oral antibiotics prophylaxis before a biopsy. -- Problem -- The standard biopsy procedure is related with the transfer of intestinal bacterial flora to the blood and prostate. In the recent years, infectious complication rate following prostate biopsies continues to increase. The reason for this phenomenon is the increasing bacterial resistance to the standard oral antimicrobial prophylaxis. Patients undergoing prostate biopsy are exposed to urinary tract infections, prostatitis, and even severe septic complications. Annual treatment cost of prostate biopsy-related complications and insurance payouts is estimated at 1.7 bn USD in the USA and Europe. -- Solution -- Prostate biopsy needle that delivers the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start. This application method allows to use a more effective antibiotic which is not allowed for oral prophylaxis.

NUADU is a state-of-the-art Assessment Platform and content aggregator, tailored for educational institutions worldwide, leveraging AI for personalized learning experiences. We are measuring and enhancing learning outcomes in education while simultaneously optimizing economic metrics by reducing costs and student churn.

Trusted Twin is a Customer Data Hub connecting Data Providers with Data Users in a secure, privacy-centric environment. Data Providers can monetize their data at scale while Data Users gain real-time access to high quality customer data letting them increase sales. 

Recruitment Smart is a Generative AI tech startup on a global mission of bringing the AI revolution in improving Talent Acquisition, with operations in 70+ countries. Fusing the expertise of industry veterans from recruitment and tech, our solutions are powered by the cutting-edge Generative AI technology. We are committed to addressing diverse customer needs, and craft products finely attuned to the demands of enterprise, mid-size, and startup businesses. Our talent intelligence solutions seamlessly integrates across platforms at organisational scales. At Recruitment Smart, we redefine the future of recruitment by marrying AI innovation with expertise. Join us on our mission to reshape the global recruitment landscape, where technology meets talent seamlessly for unparalleled insights and success.

DEBN (Drug-Eluting Biopsy Needle) is a medical company developing a novel prostate biopsy needle for urologists which will reduce infectious complication rate. -- Overview -- Prostate cancer is the most common malignancy diagnosed among men in developed countries. The prostate biopsy is a gold standard for detecting this cancer. During this procedure, urologists use a disposable biopsy needle to collect samples of tissue for further analysis. Due to the invasive method of diagnosis patients are advised for oral antibiotics prophylaxis before a biopsy. -- Problem -- The standard biopsy procedure is related with the transfer of intestinal bacterial flora to the blood and prostate. In the recent years, infectious complication rate following prostate biopsies continues to increase. The reason for this phenomenon is the increasing bacterial resistance to the standard oral antimicrobial prophylaxis. Patients undergoing prostate biopsy are exposed to urinary tract infections, prostatitis, and even severe septic complications. Annual treatment cost of prostate biopsy-related complications and insurance payouts is estimated at 1.7 bn USD in the USA and Europe. -- Solution -- Prostate biopsy needle that delivers the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start. This application method allows to use a more effective antibiotic which is not allowed for oral prophylaxis.

Alfabeat is seed fund for enterprise software companies from Central and Eastern Europe, with a track record including a unicorn, and backed by successful founders who built global companies